Dr. Nita Patel, Director of antibody detection and vaccine development, will build a vial with a coronavirus vaccine, COVID-19, at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the vaccine-developing laboratories for the coronavirus, COVID- 19.
Anndra Caballero-Reynolds | AFP | Getty Images
The Covid-19 vaccine at Novavax was 96% effective in preventing cases caused by the original version of the coronavirus in a late lawsuit filed in the United Kingdom, the company said Thursday. moving it a step closer to regulatory agreement.
There were no cases of serious illness or death among those vaccinated.
The vaccine was also about 86% effective in protecting against the more commonly detected infectious virus that is now common in the UK. It was about 90% effective overall, combining data from people with both strains of the coronavirus.
Novavax shares jumped 22% in after-hours trading to $ 229. They traded below $ 10 on Jan. 21, 2020, when the company announced that they were developing a coronavirus vaccine.
In a smaller trial conducted in South Africa – where volunteers were relatively newer, more infectious who were widely circulating there and spreading around the world – the Novavax vaccine was only about 55% effective but still prevented serious illness and death.
Results from the final UK test were largely in line with interim data released in January.
The company plans to use the data to apply for regulatory approval in different countries. It is unclear when it will seek U.S. approval or whether regulators will seek to complete an ongoing test in the United States.
The UK trial, which enrolled more than 15,000 people aged 18 to 84, evaluated the effectiveness of the vaccine at a time when the high spread of the UK virus is now widely circulated.
The effectiveness of the picture in the South African trial fell to about 49% when the analysis included data from HIV-positive participants.
Novavax began an ongoing submission of its vaccine data to the UK Medicines and Healthcare products Regulatory Agency (MHRA) in mid-January, which should help speed up the licensing process.
The vaccine could be cleared for use in the United States as early as May if U.S. regulators decide that UK data is sufficient to make a decision. It could take a month or two longer if they ask him to see data from the U.S. test first, his boss told Reuters earlier this month.
Novavax vaccine fruit plants should be fully operational by April, officials said in an investor call in March. The drug dealer expects tens of millions of doses to be collected and ready for disposal in the United States when licensed, Chief Stanley Erck told Reuters.
Novavax plans to carry out its dual-vaccine vaccine at eight manufacturing sites, including the Serum Institute of India.
If authorized, it would follow three previously approved Covid-19 vaccines for use in Britain from Pfizer and its partner BioNTech, Moderna and the AstraZeneca model developed by Oxford University.
Final results from the Novavax test are more promising as Covid-19 daily deaths are spinning in Britain, possibly led by the UK variable.